A*STAR Infectious Diseases Labs (A*STAR IDL)

Region-specific stem cells may not only act as starting points for colorectal cancer, but also offer new clues for early detection and treatment.

As the Chairman of Singapore’s lead R&D public sector agency, Chorh Chuan Tan outlines A*STAR’s strategic role within a new phase of national strategic priorities in research, innovation and enterprise.

A unique RNA structure shared across SARS-CoV-2 variants may contribute to viral fitness, offering a potential target for new antiviral treatments.

An anti-hypertension drug could potentially be repurposed as a more affordable treatment for liver cancer.

Whether combating global viral threats or advancing next-generation telecommunications, the A*STAR winners of the 2025 President’s Science and Technology Awards showcase the talent and drive at the foundations of world-class research excellence.

In recognition of their research excellence, leadership and impact both locally and globally, ten leading A*STAR researchers have been awarded the A*STAR Distinguished Fellowship and Fellowships.

A new ‘liquid lipid’ approach that penetrates the nose’s mucus barrier could lead to needle-free, nasal spray-based mRNA vaccines.

This year, the National Research Foundation Singapore is empowering three A*STAR researchers to push the boundaries of science.

Researchers uncovered how specialised stem cells act as building blocks for the esophagus, shaping its development and offering insights into treating related diseases.

A*STAR researchers find that ordinary communications between immune cells during chikungunya virus infection can drive joint inflammation seen in the disease.

Through its focus on attracting, developing and retaining talents in science and technology, A*STAR is helping to build a rich national ecosystem of research, innovation and enterprise.

Antibodies in mucous membranes may be key in protecting against SARS-CoV-2 variants, pointing to the need for COVID-19 vaccines that target these antibody responses.